Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio™ Initiative

Business Wire

a day ago

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations,announced today that it has signed a custody agreement with Crypto.com, a global leader in digital asset platforms, to establish a custodial crypto account. The agreement is a foundational step in the broader planned rollout of bitXbio™ —Aditxt's crypto-native social platform bridging Fintech and Biotech.
Under the agreement Crypto.com will serve as the custodian for Aditxt's proposed digital treasury, supporting its planned strategy to back biotech innovation with a reserve of digital assets including Bitcoin. Additionally, ADTX common stock is now tradable through Crypto.com's broker-dealer, providing a more seamless opportunity for crypto native retail and institutional investors to trade ADTX.
Crypto.com Custody, Crypto.com's institutional-grade custody offering, will provide the custodial services. Crypto.com Custody offers custody services to eligible institutions and high-net-worth clients through a comprehensive, end-to-end solution with safety and security at its core.
'Businesses across industries are strategically planning for the future with digital asset treasuries,' said Eric Anziani, President and Chief Operating Officer of Crypto.com. 'We are pleased to support Aditxt and its pioneering bitXbio initiative with our best-in-class custodial capabilities and as they look to engage crypto native traders.'
The initiative is part of Aditxt's bitXbio™ platform, which aims to expand access to innovations in immune reprogramming (Adimune), early cancer detection (Pearsanta), women's health (Adifem) and other innovations with the potential of addressing some of the most pressing health challenges.
'We believe that this agreement is a key step in aligning our biotech assets with a next-generation financial infrastructure,' said Amro Albanna, Co-founder and CEO of Aditxt. 'By engaging Crypto.com for custody and access, we are laying the foundation for a new kind of platform—where value is not only created through innovation but made accessible to all through digital finance.'
About Crypto.com
Founded in 2016, Crypto.com is trusted by more than 150 million customers worldwide and is the industry leader in regulatory compliance, security and privacy. Our vision is simple: Cryptocurrency in Every Wallet™. Crypto.com is committed to accelerating the adoption of cryptocurrency through innovation and empowering the next generation of builders, creators, and entrepreneurs to develop a fairer and more equitable digital ecosystem.
About Aditxt, Inc.
Aditxt, Inc. is a social innovation platform accelerating promising health innovations. Aditxt's ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. The Company currently operates two programs focused on immune health and precision health. Through the proposed acquisition of Evofem under the July 2024 Amended and Restated Merger Agreement between Evofem, Aditxt and Adifem, as amended (the "A&R Merger Agreement"), Aditxt aims to introduce an additional program dedicated to women's health. The companies are working toward a targeted close in the second half of 2025. The closing of the transaction with Evofem is subject to several conditions, including but not limited to approval of the transaction by Evofem's shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Evofem, which includes approximately $15.0 million required to satisfy Evofem's senior secured noteholder; should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close.
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "achieving," "advancing", "aim," "are working to," "believe," "completing," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated availability of funds to pursue the purchase of digital assets; Aditxt's ability to successfully execute its mission to accelerate and monetize promising health innovations, and magnitude thereof; Aditxt's ability to complete the proposed initial public offering of Pearsanta on the proposed timeline, if at all; Aditxt's ability to close the planned acquisition of Evofem, including to meet all closing conditions, and the timing thereof; and anticipated availability of funds to pursue the purchase of digital assets by Aditxt. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in each company's SEC filings, including Aditxt's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 31, 2025, and any subsequent Form 10-Q filings. All forward-looking statements are expressly qualified in their entirety by such factors. Aditxt undertakes no duty to update any forward-looking statement except as required by law.
For more information, please visit www.aditxt.com.
Follow Aditxt on: